Phase II study of Chidamide and Tislelizumab in advanced non-small cell lung cancer
Latest Information Update: 14 Dec 2023
At a glance
- Drugs Tislelizumab (Primary) ; Tucidinostat (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 24 Oct 2023 Results (At data cut off Apr 22, 2023, n=19) presented at the 48th European Society for Medical Oncology Congress
- 10 Jul 2023 New trial record
- 06 Jun 2023 Results (n=20; At the data cut-off February 10, 2023) assessing the efficacy and safety of chidamide plus tislelizumab combined with chemotherapy in advanced NSCLC, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.